Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion

Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies